Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

Marketable Securities

6 Months Ended

Jun. 30, 2011

4.	Marketable Securities

Cost and fair value of the Company's marketable securities are as follows:

Securities available-for-sale	Cost Basis		Gross Unrealized Losses			Fair Value
June 30, 2011:
State and municipal obligations	$	1,950,000	$	-		$	1,950,000

December 31, 2010:
State and municipal obligations	$	2,453,960	$	(2,340	)	$	2,451,620

Amortized cost and fair value at June 30, 2011 by contractual maturity are shown below. Expected maturities will differ from contractual maturities because the Company may redeem certain securities at par. During the three and six months ended June 30, 2011, the Company sold $8,500,000 of securities at par and the total amount that was reclassified from accumulated comprehensive loss into net loss was $3,960. The unrealized loss on marketable securities for the three and six months ended June 30, 2011 was $260 and $1,620, respectively.

Maturity		Cost Basis				Gross Unrealized Losses				Fair Value
10 years or more		$	1,950,000				-			$	1,950,000

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References + Details